At the Haemophilia Reference Centre Directors meeting it was suggested the implication was that the cheaper (Kryobulin produced in the US) product carried the higher risk of plasma viral hepatitis which worried some Directors.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Professor E.K. Blackburn
Dr Irvine Wiliam Delamore
Dr G I C Ingram: Dr Peter M Jones
Dr Charles Rizza
Professor Edward G D Tuddenham